China’s 2024 IP Reforms Reshape Innovation Landscape
In 2024, China introduced a series of intellectual property reforms that have drawn significant attention from innovators, legal professionals, and technology-driven industries worldwide. Among the most consequential changes was the rollout of patent term extensions (PTE) for pharmaceuticals, a mechanism designed to offset the time lost during regulatory approval. This approach, long established in the United States under the Hatch-Waxman Act of 1984, was integrated into Chinese law as part of an economic agreement with the US in January 2020 and became operational with detailed guidelines issued in January 2024.
Under the new framework, qualifying patents covering new drugs can gain up to five additional years of protection, with the total effective term capped at 14 years from the date of marketing approval. The scope of eligibility spans product patents, preparation method patents, and medical use patents tied to an active pharmaceutical ingredient in a “new drug.” To secure a PTE, the patent must remain valid, must not have been previously extended, and must contain drug-related technical solutions. Only one patent per drug can be extended, and the China National Intellectual Property Administration (CNIPA) conducts a formal examination of requests, allowing for observations or amendments before issuing a decision. Importantly, the extended protection applies narrowly to the approved indication; a new indication may justify a separate PTE but will only cover that specific use.
Parallel to the pharmaceutical reforms, China deployed the Copyright AI Intelligent Review Tool (版权AI智审), a sophisticated artificial intelligence system aimed at strengthening copyright enforcement. This tool addresses a persistent challenge in IP law: efficiently verifying originality and detecting infringement. Leveraging advanced image recognition, it performs “image-to-image” searches to trace the origins of visual works and identify their original creators. It also quantifies the degree of innovation and measures similarity between images, supporting infringement determinations. Integrated into court management platforms, the system equips judges with analytical capabilities during proceedings, accelerating case resolution and improving accuracy. Its design prioritizes usability, reducing training needs for court staff, and lowers litigation costs by streamlining evidence gathering. By automating key aspects of analysis, it reduces human error and bolsters enforcement, with current applications focused on image copyright cases and potential expansion into broader domains.
Ethical considerations in IP practice were reinforced through the revised Rules for the Implementation of the Patent Law, effective 20 January 2024. Article 11 explicitly states: “The patent application shall be made in accordance with the good-faith principle.” This requirement seeks to prevent abuse of patent and trademark systems by mandating genuine inventive activity and prohibiting filings intended to harm public interests. In patent examination, the principle—applied since June 2021—guards against falsified applications. For trademarks, it has been in place since 2013, with detailed provisions issued in 2019 to curb practices such as registering marks without intent to use or imitating well-known brands. CNIPA retains authority to reject applications violating this principle, thereby promoting transparency and integrity in IP administration.
On 29 October 2024, CNIPA released Guidelines on Trade Mark License Recordal Procedure, clarifying legal requirements for recording trademark licenses. A trademark license grants permission from the owner to another party to use the mark under defined conditions. The licensor must report the license for recordal, as unrecorded licenses cannot be enforced against third parties acting in good faith. The guidelines specify that license agreements may detail trademark information, goods or services covered, license form and term, restrictions, quality guarantees, and breach liabilities. CNIPA announces recorded licenses meeting regulatory standards, with public access provided through its official database.
Further procedural efficiency emerged in April 2024 when CNIPA joined the Patent Prosecution Highway (PPH) Improvement Initiative, a collaborative effort among the five leading IP offices—China, the United States, Europe, Japan, and the Republic of Korea. The initiative aims for an average examiner-to-applicant response time of three months, including from PPH request grant to first official action. This commitment enhances predictability and speed in patent examination, benefiting applicants through reduced processing times and coordinated work sharing between jurisdictions. For industries where rapid protection of innovation is critical, such as aerospace, robotics, and advanced materials, these measures promise a more streamlined path from concept to market.
